AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19375893
Drug: Ziprasidone 40
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 40 mg/d
Trial: 19375893
Drug: Ziprasidone 80
RxNorm normalized name: ziprasidone 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 80 mg/d
Trial: 19375893
Drug: Ziprasidone 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 120 mg/d
Trial: 7901267
Drug: Protective agent
RxNorm normalized name: PROTECTIVE AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protective agent during short-term NSAID use
Trial: 3096643
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (Transiderm‐Nitro 25 mg/24 hours)
Trial: 23533227
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel (2 doses targeting either 400-550 ng/dL or 600-1000 ng/dL)
Trial: 20546622
Drug: Anti-platelet drug
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-platelet drug use (50% of diabetic patients)
Trial: 20546622
Drug: Platelet inhibitor
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet inhibitor use (including aspirin and non-aspirin)
Trial: 18811599
Drug: Darifenacin 7.5
RxNorm normalized name: darifenacin 7.5 MG
DrugBank: Darifenacin (DB00496)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Darifenacin 7.5 mg once daily (up-titrated to 15 mg after 2 weeks if needed) for up to 12 weeks
Trial: 2097485
Drug: Fentanyl 20
RxNorm normalized name: fentaNYL 200 mcg buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 20 micrograms (0.4 ml) with 0.5% heavy marcaine 2.0 ml
Trial: 2097485
Drug: Control group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group: 0.5% heavy marcaine 2.0 ml with CSF 0.4 ml
Trial: 6457568
Drug: 2% solution
RxNorm normalized name: Lidomar 2% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% solution of erythromycin
Trial: 27119575
Drug: PD 0348292
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD 0348292 (2.5-150 mg)
Trial: 27119575
Drug: PD 0348292
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD 0348292 (5-30 mg) every 12 hours
Trial: 27119575
Drug: PD 0348292
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PD 0348292 (5 mg) single dose
Trial: 25056151
Drug: Immediate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate therapy group receiving physical therapy (maximum of 12 sessions of 30 min for a 6-week program)
Trial: 25056151
Drug: Delayed therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed therapy group (6 weeks delay before starting therapy)
Trial: 22033354
Drug: Quasi-long pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quasi-long pulse and Q-switched Nd:YAG laser treatment with topically applied carbon suspension
Trial: 12390708
Drug: rhEGF ophthalmic
RxNorm normalized name: Hu-rhEGF-rP64k/Mont
DrugBank: Hu-rhEGF-rP64k/Mont (DB15781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhEGF ophthalmic solution
Trial: 12390708
Drug: Drug vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug vehicle (control)
Trial: 9702646
Drug: Psychological preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological preparation (demonstration of materials, use of a doll, or a book with photographs)
Trial: 7737255
Drug: Casodex (ICI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casodex (ICI 176,334) monotherapy
Trial: 16699276
Drug: Cascabel chilli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cascabel chilli (3 g daily, 880 ppm capsaicin)
Trial: 16699276
Drug: Ancho chilli
RxNorm normalized name: Chilli pepper
DrugBank: Capsicum (DB10897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ancho chilli (3 g daily, 488 ppm capsaicin)
Trial: 15297049
Drug: Hexavalent outer
RxNorm normalized name: meningococcus B, outer membrane vesicle vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent outer membrane vesicle (OMV) vaccine (HexaMen) containing six different porin A (PorAs)
Trial: 15297049
Drug: Hexavalent outer
RxNorm normalized name: meningococcus B, outer membrane vesicle vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent outer membrane vesicle (OMV) vaccine (HexaMen)
Trial: 7867679
Drug: Acrivastine 24
RxNorm normalized name: Acrivastine
DrugBank: Acrivastine (DB09488)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acrivastine 24 mg
Trial: 7867679
Drug: Acrivastine 8
RxNorm normalized name: acrivastine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acrivastine 8 mg + pseudoephedrine 60 mg
Trial: 779391
Drug: Pethidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (1 mg/kg i.v.)
Trial: 779391
Drug: Anileridine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anileridine (0.25 mg/kg)
Trial: 28237860
Drug: α glucosidase
RxNorm normalized name: alpha glucosidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α glucosidase inhibitor (αGI)
Trial: 24894652
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg), Trastuzumab (8 mg/kg loading dose followed by 6 mg/kg), Docetaxel (100 mg/m2 initially, later amended to 75 mg/m2) every three weeks for six cycles
Trial: 23131911
Drug: Honey barrier
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honey barrier cream
Trial: 23131911
Drug: Zinc oxide
RxNorm normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc oxide ointment
Trial: 15751004
Drug: Encapsulated warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated warfarin (2.5 mg tablets)
Trial: 15751004
Drug: Nonencapsulated warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonencapsulated warfarin (2.5 mg tablets)
Trial: 12028870
Drug: Elective stenting
RxNorm normalized name: hetastarch
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective stenting using the heparin-coated beStent
Trial: 10598553
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid administered orally at 25 mg/m2 and 125 mg/m2
Trial: 10598553
Drug: Repetitive oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive oral administration of folic acid every 6 hours
Trial: 10598553
Drug: Repetitive oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive oral administration of folic acid
Trial: 2165860
Drug: Spectinomycin (2-gm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectinomycin (2-gm single dose)
Trial: 2165860
Drug: Co-trimoxazole (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (two tablets twice daily for seven days)
Trial: 722696
Drug: Placebo systems
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo systems releasing no hormone
Trial: 31150916
Drug: Brazil nut
RxNorm normalized name: Brazil nut
DrugBank: Brazil nut (DB10510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brazil nut intake (1 Brazil nut per day, approximately 1261 μg/Se) for 2 months
Trial: 27726029
Drug: Cogstate computerized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cogstate computerized battery assessment during the first month of induction chemotherapy
Trial: 24249817
Drug: Probiotic combination
RxNorm normalized name: PROBIOTIC COMBINATION CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic combination (Bifidobacterium infantis, Streptococcus thermophilus, and Bifidobacterium lactis, 1 × 10(9) total organisms)
Trial: 3562890
Drug: one cycle
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one cycle of combination chemotherapy + radiation therapy + 5 cycles of combination chemotherapy
Trial: 22943819
Drug: C.E.R.A. once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C.E.R.A. once every 4 weeks by subcutaneous administration
Trial: 22943819
Drug: EPO 1-3
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO 1-3 times weekly
Trial: 18386580
Drug: Shenqi Fuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi Fuzheng Injection (SFI) combined with chemotherapy
Trial: 18386580
Drug: Chemotherapy (CTF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CTF regimen)
Trial: 31474458
Drug: Omadacycline (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omadacycline (450 mg orally every 24 h for 48 h then 300 mg orally every 24 h for 7-14 days)
Trial: 31474458
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg orally every 12 h for 7-14 days)
Trial: 24499441
Drug: LET 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LET 2.5 mg/day
Trial: 24499441
Drug: LET 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LET 2.5 mg/day + ZOL 4 mg every 4 weeks (total of 7 infusions)
Trial: 19745216
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg of hemagglutinin antigen by intramuscular injection
Trial: 19745216
Drug: 30 microg
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microg of hemagglutinin antigen by intramuscular injection
Trial: 19745216
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg and 30 microg doses after the second dose
Trial: 19745216
Drug: 15 microg
RxNorm normalized name: Tafluprost 15 microgram/mL eye drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 microg and 30 microg doses
Trial: 17513662
Drug: Neck extension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neck extension (5 mL of contrast injected)
Trial: 17513662
Drug: Neck flexion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neck flexion (5 mL of contrast injected)
Trial: 17513662
Drug: Neutral position
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral position (5 mL of contrast injected)
Trial: 14759294
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of buserelin
Trial: 14759294
Drug: s.c. administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s.c. administration of buserelin
Trial: 9571968
Drug: 5'-DFUR 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'-DFUR 600 mg/body/day with radiotherapy and SPG (20 mg twice/week or 40 mg/week)
Trial: 9571968
Drug: 5'-DFUR 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'-DFUR 800 mg/body/day with radiotherapy and SPG (20 mg twice/week or 40 mg/week)
Trial: 9571968
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of radiotherapy, 5'-DFUR and SPG
Trial: 7917580
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg alendronate daily for 6 months
Trial: 7917580
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg alendronate daily for 6 months
Trial: 27180680
Drug: Dairy milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy milk (2 or 4 servings, 473 and 946 ml)
Trial: 27180680
Drug: Water (473
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (473 ml)
Trial: 20157835
Drug: Quality of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quality of Life Therapy (QoLT)
Trial: 15480852
Drug: L-carnitine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (3 g/d)
Trial: 15480852
Drug: Creatine (6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (6.75 g/d)
Trial: 10493319
Drug: Colesevelam hydrochloride
RxNorm normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam hydrochloride 1.5 g/d
Trial: 10493319
Drug: Colesevelam hydrochloride
RxNorm normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam hydrochloride 3.75 g/d
Trial: 10493319
Drug: Colesevelam hydrochloride
RxNorm normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam hydrochloride 3.0 g/d
Trial: 8725997
Drug: Fluconazole 50
RxNorm normalized name: fluconazole 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 50 mg thrice weekly
Trial: 1782952
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium chloride (80 mmol.24 h‐1)
Trial: 7261665
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg sulindac per day
Trial: 7261665
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg ibuprofen per day
Trial: 25632091
Drug: Expensive placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expensive placebo (subcutaneous novel injectable dopamine agonist placebo)
Trial: 25632091
Drug: Cheap placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cheap placebo (subcutaneous novel injectable dopamine agonist placebo)
Trial: 19592632
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy (premeal insulin aspart)
Trial: 19592632
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and Repaglinide (in patients with IGT)
Trial: 15924593
Drug: On-demand esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On-demand esomeprazole 20 mg
Trial: 15924593
Drug: Continuous esomeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous esomeprazole 20 mg once-daily
Trial: 15924593
Drug: Continuous ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous ranitidine 150 mg twice-daily
Trial: 12765745
Drug: Melperone 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melperone 100 mg/day
Trial: 12765745
Drug: Melperone 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melperone 400 mg/day
Trial: 12765745
Drug: Melperone (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melperone (both doses)
Trial: 6864377
Drug: 2 and
RxNorm normalized name: VITAMIN B12 AND FOLIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 and 3 hours after administration
Trial: 28701205
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (Art therapy and Music reminiscence)
Trial: 26463607
Drug: Ulinastatin (5,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (5,000 U/kg intravenous injection before skin incision and at the end of operation)
Trial: 22920723
Drug: Porcine placental
RxNorm normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Porcine placental extract (PPE) - 3 capsules/day for the first 12 weeks, then 6 capsules/day for the next 12 weeks
Trial: 22920723
Drug: Toki-shakuyaku-san (TJ23)
RxNorm normalized name: San Qi
DrugBank: Panax notoginseng root (DB14304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toki-shakuyaku-san (TJ23) - control group, 24 weeks of open treatment
Trial: 15842594
Drug: Sedation (meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedation (meperidine 62.5 mg and midazolam 2.5 mg)
Trial: 12456070
Drug: Cerebrolysin (Cere)
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (Cere) 30 ml infusion, five days/week for six weeks
Trial: 12456070
Drug: Placebo infusion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion, five days/week for six weeks
Trial: 8759491
Drug: Gold or
RxNorm normalized name: Niferex Gold Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold or methotrexate (MTX) therapy
Trial: 1882158
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (specific antibiotics not mentioned)
Trial: 1882158
Drug: Various antibiotics
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various antibiotics tested (specifics not mentioned)
Trial: 25092393
Drug: 30-mg fimasartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-mg fimasartan
Trial: 20308769
Drug: Cholecalciferol granules
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol granules (60,000 IU) orally once in two months (two‐monthly D₃ group)
Trial: 20308769
Drug: Cholecalciferol granules
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol granules (60,000 IU) orally once a month (one‐monthly D₃ group)
Trial: 20308769
Drug: Cholecalciferol granules
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol granules (60,000 IU) orally once in two months (two‐monthly D₃ group) in USES subjects
Trial: 20308769
Drug: Cholecalciferol granules
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol granules (60,000 IU) orally once a month (one‐monthly D₃ group) in USES subjects
Trial: 10212791
Drug: Intra-arterial chemotherapy
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial chemotherapy combined with radiotherapy
Trial: 2112877
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg recombinant tissue‐type plasminogen activator (rt‐PA) intravenously over 3 hours
Trial: 306577
Drug: Oral ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ampicillin
Trial: 306577
Drug: Sulfonamide vaginal
RxNorm normalized name: 2-acetylamino-1,3,4-thiadiazole-5-sulfonamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfonamide vaginal cream
Trial: 27594381
Drug: Probiotic Bifidobacterium
RxNorm normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Bifidobacterium breve BBG-001 (6.7 × 10(7) to 6.7 × 10(9) CFU per dose)
Trial: 27594381
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 ml of one‐eighth‐strength infant formula Neocate)
Trial: 18467115
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg/day (Control)
Trial: 15986863
Drug: Partially hydrolyzed
RxNorm normalized name: Human Skin Proteins, Partially Hydrolyzed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partially hydrolyzed guar gum (PHGG) 10 g/day
Trial: 2071787
Drug: WEB 2086
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: WEB 2086 (10 mg)
Trial: 2071787
Drug: WEB 2086
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: WEB 2086 (40 mg)
Trial: 2071787
Drug: WEB 2086
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: WEB 2086 (100 mg)
Trial: 26472752
Drug: Obinutuzumab 2000
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab 2000 mg
Trial: 20420663
Drug: Portal survey
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Portal survey technique including semi-structured questionnaires, breath alcohol test, drug assumption tests, and reaction time measurement using a driving simulator.
Trial: 18538773
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of 0.75% ropivacaine
Trial: 9333593
Drug: Potassium and
RxNorm normalized name: Potassium and/or potassium compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium and magnesium treatment
Trial: 3551602
Drug: Nifedipine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (mean dose, 79.6 mg per day)
Trial: 3551602
Drug: Propranolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (mean dose, 198.4 mg per day)
Trial: 30316590
Drug: 90:10 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90:10 treatment (extruded high-fat pellet mixed with low-fat control pellet)
Trial: 30316590
Drug: 80:20 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80:20 treatment
Trial: 30316590
Drug: 70:30 treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70:30 treatment, HFSP, and control
Trial: 30316590
Drug: 90:10 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90:10 treatment
Trial: 21624240
Drug: Cod liver
RxNorm normalized name: Cod Liver Oil
DrugBank: Cod liver oil (DB11321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod liver oil supplementation (0.5 g every 15 days for six times)